Phase 3 Clinical Trials With Primary Completion Dates in December 2017
This is a list of Phase 3 trials with primary completion dates in December 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2017-12-01 | Phase 3 | NCT00550238 | A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis |
| ALKS | Alkermes plc | 2017-12-01 | Phase 3 | NCT02141399 | A Long-Term Safety Study of ALKS 5461 |
| AMRN | Amarin Corporation plc | 2017-12-01 | Phase 3 | NCT01492361 | A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. |
| AQXP | Aquinox Pharmaceuticals, Inc. | 2017-12-01 | Phase 3 | NCT02858453 | Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome |
| ARGS | Argos Therapeutics, Inc. | 2017-12-01 | Phase 3 | NCT01582672 | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma |
| AXSM | Axsome Therapeutics, Inc. | 2017-12-01 | Phase 3 | NCT02504008 | CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 |
| CERS | Cerus Corporation | 2017-12-01 | Phase 3 | NCT01740531 | Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion |
| CTRV | ContraVir Pharmaceuticals Inc | 2017-12-01 | Phase 3 | NCT02412917 | A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia |
| CVM | Cel-Sci Corporation | 2017-12-01 | Phase 3 | NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity |
| DEPO | Depomed, Inc. | 2017-12-01 | Phase 3 | NCT02081391 | An Efficacy and Safety Study of Tapentadol in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Participants |
| EARS | Auris Medical Holding AG | 2017-12-01 | Phase 3 | NCT02040194 | AM-101 in the Treatment of Acute Tinnitus 3 |
| ENDP | Endo International plc | 2017-12-01 | Phase 3 | NCT01210352 | Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects |
| EYEG | Eyegate Pharmaceuticals, Inc. | 2017-12-01 | Phase 3 | NCT02517619 | Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis |
| INSY | Insys Therapeutics, Inc. | 2017-12-01 | Phase 3 | NCT02318602 | Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder |
| INSY | Insys Therapeutics, Inc. | 2017-12-01 | Phase 3 | NCT02138409 | Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting |
| KERX | Keryx Biopharmaceuticals, Inc. | 2017-12-01 | Phase 3 | NCT02492620 | Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D |
| MD | Mednax, Inc | 2017-12-01 | Phase 3 | NCT02534077 | Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants |
| MESO | Mesoblast Limited | 2017-12-01 | Phase 3 | NCT02336230 | A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD |
| MMSI | Merit Medical Systems, Inc. | 2017-12-01 | Phase 3 | NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer |
| NBRV | Nabriva Therapeutics plc | 2017-12-01 | Phase 3 | NCT02813694 | Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia |
| NKTR | Nektar Therapeutics | 2017-12-01 | Phase 3 | NCT02367820 | Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain |
| OHRP | Ohr Pharmaceuticals, Inc. | 2017-12-01 | Phase 3 | NCT02727881 | Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD |
| ONTX | Onconova Therapeutics, Inc. | 2017-12-01 | Phase 3 | NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine |
| PEN | Penumbra, Inc. | 2017-12-01 | Phase 3 | NCT01636453 | The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms |
| PTCT | PTC Therapeutics, Inc. | 2017-12-01 | Phase 3 | NCT02090959 | Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy |
| PTCT | PTC Therapeutics, Inc. | 2017-12-01 | Phase 3 | NCT01557400 | Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada |
| RVNC | Revance Therapeutics, Inc. | 2017-12-01 | Phase 3 | NCT03014635 | Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines |
| RVNC | Revance Therapeutics, Inc. | 2017-12-01 | Phase 3 | NCT03014622 | Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines |
| SGEN | Seattle Genetics, Inc. | 2017-12-01 | Phase 3 | NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas |
| SNGX | Soligenix, Inc. | 2017-12-01 | Phase 3 | NCT02448381 | FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2017-12-01 | Phase 3 | NCT02953340 | Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER) |
| TTPH | Tetraphase Pharmaceuticals, Inc. | 2017-12-01 | Phase 3 | NCT02784704 | Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections |
| VBLT | Vascular Biogenics Ltd. | 2017-12-01 | Phase 3 | NCT02511405 | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) |
| VTL | Vital Therapies, Inc. | 2017-12-01 | Phase 3 | NCT02612428 | Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD |